查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2003052

生物製药合约开发和生产组织 (CDMO) 市场：2026-2032 年全球市场预测（按服务类型、表现系统、治疗领域、开发阶段和最终用户划分）

Biologics Contract Development & Manufacturing Organization Market by Service Type, Expression System, Therapeutic Category, Development Phase, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 183 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2025 年生技药品合约开发和生产 (CDMO) 市场价值为 114 亿美元，预计到 2026 年将成长至 122.6 亿美元，复合年增长率为 7.71%，到 2032 年将达到 191.8 亿美元。

主要市场统计数据
基准年 2025 114亿美元
预计年份：2026年 122.6亿美元
预测年份 2032 191.8亿美元
复合年增长率 (%) 7.71%

一篇精闢而富有洞察力的介绍文章重点阐述了技术、监管和商业性因素如何重塑生物製药 CDMO伙伴关係和业务重点。

生物製药合约开发与生产（CDMO）产业正经历一场策略重组，其驱动力来自技术进步、日益严格的监管要求以及日益激烈的竞争格局。各种规模的机构都在重新评估与外部生产商从药物发现到商业化的合作方式，同时应对供应链脆弱性和人才短缺等挑战。先进的表达系统、不断发展的治疗方法以及研发人员的营运需求相互作用，共同塑造了品质、速度和柔软性的新标准。现有企业必须满足这些标准才能保持竞争力。

快速的技术进步、策略性合併以及赞助商期望的变化如何创造生物製药製造领域新的竞争格局和伙伴关係模式。

随着申办方和服务供应商诸如快速过渡到临床试验、更严格的监管审查以及为支持多样化治疗方法而需要灵活的生产能力等新挑战，生物製药生产生态系统正经历着变革性的变化。表达系统和下游製程的进步提高了产量和产品均一性，而分析技术和数位化过程监控的同步发展则提高了人们对可追溯性和品质保证的期望。这些技术变革与策略转变相辅相成，越来越多的申办者从简单的外包转向包含共同开发和风险共担安排的策略伙伴关係。

了解预期中的贸易政策变化和关税调整将如何重塑生物製药开发和製造中的采购、产能分配和供应商策略。

预计2025年的关税变化和贸易政策调整将为生物製药供应链、筹资策略和跨境生产伙伴关係带来一系列复杂的考量。关税可能对关键原材料、一次性耗材以及填充、精加工和包装流程中特定组件的到货成本产生重大影响，迫使企业重新评估其采购区域和合约条款。为此，赞助商和契约製造可能会加快供应商多元化，建立区域采购中心，并重新谈判长期供应合同，以减轻潜在的成本波动并维持生产计划。

基于细分的洞察揭示了服务类型、表达平台、治疗领域、开发阶段需求和最终用户概况如何决定 CDMO 的能力和策略重点。

从精细的市场区隔观点，不同服务类型、表达系统、治疗领域、研发阶段和最终用户的需求驱动因素、营运要求和价值提案有显着差异。基于服务类型，市场可区分药品製剂服务及原料原料药服务，二者均需特定的技术能力及监管流程，因此合作伙伴的选择标准也各不相同。基于表达系统，供应商和申办者需权衡哺乳动物细胞平台和微生物平台之间的优劣。对于含有复杂聚醣的蛋白质，哺乳动物细胞系统需要对Cho、Hek和Ns0细胞株拥有深厚的专业知识；而大肠桿菌和酵母等微生物方法则擅长快速、经济高效地生产结构相对简单的分子。

区域趋势分析显示了美洲、欧洲、中东和非洲以及亚太地区生物製药製造的独特优势和战略考量。

区域趋势持续影响全球生物製药产业的投资决策、企业发展和伙伴关係策略。美洲的优势包括完善的法规结构、充足的设施扩建资金以及众多需要大规模哺乳动物细胞生产能力的赞助商。该地区通常优先考虑与国内临床开发项目整合，并透过本地能力建设来增强供应链的韧性。欧洲、中东和非洲（EMEA）则呈现出多元化的环境，监管协调的努力与区域专业知识并存，从而能够提供从利基市场到商业规模的高品质契约製造服务，并促进各国领先研究中心之间的合作。

大型和利基服务供应商的企业策略和能力建设趋势正在推动生物製药製造领域的竞争差异化和长期韧性。

在生物製药合约开发与生产（CDMO）领域，主要企业和创新型新参与企业正采取差异化策略，以确保稳定的收入来源和技术领先地位。许多成熟的供应商正在扩展其端到端能力，以期在从原料药到成品的整个工作流程中创造价值，并投资于模组化设施和一次性平台，以提高产能柔软性，同时降低初始投资的资本密集度。同时，一些公司专注于高级分析、高活性药物生产或基因和细胞疗法供应链等专业细分领域，力求在深厚的科学专业知识成为决定性竞争优势的领域占据高端地位。

在生物製药 CDMO 业务中，高阶主管和营运经理可以实施实际有效的措施来提高柔软性、降低执行风险并增强竞争优势。

在快速发展的生物製药製造生态系统中，产业领导企业可以采取果断措施，保持敏捷性、控制风险并抓住成长机会。首先，优先投资于支援多种表达系统和可扩展下游製程的灵活平台，以适应不断变化的客户需求和治疗模式。这种柔软性可以减轻重新验证的负担，并缩短技术转移週期。其次，透过包含明确管治和应急条款的多年战略合同，加强与供应商的关係，以应对贸易政策和原材料供应的波动。第三，加快数位化製程控制和先进分析技术，以提高产量、减少批次缺陷，并向监管机构证明卓越的资料完整性。

我们采用透明严谨的调查方法，结合专家访谈、文件审查和资料三角验证，为生物製药製造领域的相关人员提供检验且可操作的见解。

支持这些洞见的研究是透过一套系统性的调查方法进行的，该方法结合了有针对性的初步研究和严谨的二级资讯来源检验。初步研究包括对众多赞助商和服务供应商的技术领导者、监管事务专家和销售主管进行深入访谈，从而能够深入了解营运限制和客户决策标准。二手研究系统地考察了监管指南、专利趋势、技术白皮书和公开的企业资讯披露，将初步研究的结果置于特定背景下，以识别行业中的潜在模式。

简洁的结论强调了在不断发展的生物製药 CDMO 生态系统中取得成功所必需的策略转变、必要投资和协作方法。

总之，生物製药合约开发与生产（CDMO）产业正受到技术创新、客户偏好变化以及日益复杂的地缘政治和法规环境的重塑。这些因素正推动产业向更具策略性和一体化的伙伴关係转变，迫使服务供应商投资于灵活的平台、先进的分析能力和完善的品质系统。同时，客户也在寻求能够提供安全且多元化供应链的合作伙伴，以平衡速度和监管严格性，从而支持快速开发和长期商业化。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章：生物製药合约开发与生产组织（CDMO）市场：依服务类型划分

  • 配方
  • 原料药

第九章：生物製药合约开发和生产组织（CDMO）市场表现系统（按系统划分）

  • 哺乳动物
    • 赵
    • HEK
    • Ns0
  • 微生物
    • 大肠桿菌
    • 酵母菌

第十章：按治疗领域分類的生物製药合约开发和生产组织（CDMO）市场

  • 免疫学
  • 感染疾病
  • 神经病学
  • 肿瘤学

第十一章：生物製药合约开发与生产组织（CDMO）市场依开发阶段划分

  • 商业的
  • 第一阶段
  • 第二阶段
  • 第三阶段
  • 临床前

第十二章：生物製药合约开发与生产组织（CDMO）市场：依最终用户划分

  • 生技公司/中小型医疗保健公司
  • 合约研究机构
  • 大型製药企业

第十三章：生物製药合约开发与生产组织（CDMO）市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：生物製药合约开发与生产组织（CDMO）市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：生物製药合约开发与生产组织（CDMO）市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章：美国生物製药合约开发与生产组织（CDMO）市场

第十七章：中国生物製药合约研发生产机构（CDMO）市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie, Inc.
  • Abzena Ltd.
  • Aenova Holding GmbH
  • AGC Biologics GmbH
  • Avid Bioservices, Inc.
  • Binex Co. Limited
  • Boehringer Ingelheim International GmbH
  • Cambrex Corporation
  • Catalent, Inc.
  • Emergent BioSolutions, Inc.
  • Fujifilm Holdings Corporation
  • Icon PLC
  • JSR Life Sciences, LLC
  • Jubilant Biosys Limited
  • Lonza Group AG
  • Parexel International Corporation
  • ProBioGen AG
  • Recipharm AB
  • Rentschler Biopharma SE
  • Samsung Biologics
  • Takeda Pharmaceutical Company Limited
  • Tegra Medical
  • Thermo Fisher Scientific, Inc.
  • Toyobo Co., Ltd.
  • WuXi Biologics Inc
Product Code: MRR-957C47F9527F

The Biologics Contract Development & Manufacturing Organization Market was valued at USD 11.40 billion in 2025 and is projected to grow to USD 12.26 billion in 2026, with a CAGR of 7.71%, reaching USD 19.18 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 11.40 billion
Estimated Year [2026] USD 12.26 billion
Forecast Year [2032] USD 19.18 billion
CAGR (%) 7.71%

An incisive introduction highlighting how technological, regulatory, and commercial forces are reshaping biologics CDMO partnerships and operational priorities

The biologics contract development and manufacturing landscape is entering a period of strategic recalibration driven by technological advancement, heightened regulatory expectations, and intensified competitive dynamics. Organizations of all sizes are reassessing how they partner with external manufacturers to bring complex molecules from discovery through commercialization, while simultaneously navigating supply chain fragility and workforce constraints. The interplay between advanced expression systems, evolving therapeutic modalities, and the operational needs of developers has created new benchmarks for quality, speed, and flexibility that incumbent players must meet to remain relevant.

Against this backdrop, industry stakeholders increasingly prioritize end-to-end partnerships that deliver technical depth alongside commercial agility. Innovative service models, including integrated drug substance and drug product capabilities, are redefining customer expectations and enabling faster transitions across development phases. Furthermore, investments in single-use technologies, modular facilities, and digital process controls are not merely cost-management tactics but strategic enablers that support both scalability and regulatory compliance. Taken together, these forces are reshaping how sponsors select partners, structure contracts, and plan long-term supply strategies, setting the stage for a more resilient and innovation-driven market environment.

How rapid technological advances, strategic consolidation, and shifting sponsor expectations are creating new competitive dynamics and partnership models in biologics manufacturing

The biologics manufacturing ecosystem is experiencing transformative shifts as sponsors and service providers adapt to a new set of imperatives: faster time-to-clinic, higher regulatory scrutiny, and the need for flexible manufacturing capacity that supports diverse modalities. Advances in expression systems and downstream processing are enabling higher yields and greater product consistency, while parallel developments in analytics and digital process monitoring are elevating expectations for traceability and quality assurance. These technological shifts are complemented by strategic shifts: more sponsors are moving from transactional outsourcing to strategic alliances that embed co-development and risk-sharing arrangements.

Concurrently, market dynamics are driving consolidation and specialization. Large-scale strategic investments are being directed toward capacity that supports mammalian cell expression for complex monoclonal antibodies and cell therapy supply chains, while niche providers are differentiating through microbial systems optimized for rapid recombinant protein production. This divergence is prompting sponsors to adopt hybrid sourcing strategies that pair flexible, small-scale capacity for early-stage development with robust commercial-scale partners for later-stage manufacturing. As a result, long-term supplier relationships, investment in platform technologies, and the ability to pivot between expression systems and development phases are becoming core determinants of competitive advantage. Policymakers and regulators are also influencing these shifts by emphasizing supply chain transparency and quality metrics, which further shapes capital allocation and operational design across the sector.

Understanding how projected trade policy shifts and tariff adjustments could reshape sourcing, capacity allocation, and supplier strategies across biologics development and manufacturing

Anticipated tariff changes and trade policy adjustments in 2025 present a complex set of considerations for biologics supply chains, procurement strategies, and cross-border manufacturing partnerships. Tariffs can materially influence the landed cost of critical raw materials, single-use consumables, and certain components of fill-finish and packaging operations, leading organizations to reassess sourcing geographies and contractual terms. In response, sponsors and contract manufacturers may accelerate supplier diversification, establish regional sourcing hubs, or renegotiate long-term supply agreements to mitigate potential cost volatility and preserve production timelines.

Beyond direct input costs, tariff-driven shifts can have second-order effects on project planning and capacity allocation. For example, higher import duties on certain equipment or consumables could incentivize onshoring of specific manufacturing steps, particularly those with specialized regulatory oversight or cold-chain dependencies. Such moves would alter capital deployment decisions and may prioritize investments in modular, relocatable assets that reduce exposure to cross-border tariff risk. Additionally, logistics complexity may rise as firms seek to avoid tariff exposure through multi-leg routing or localized warehousing, which in turn creates operational friction and potential delays. Importantly, regulatory compliance remains non-negotiable; any adjustments to sourcing or manufacturing location must account for validation requirements and supply chain transparency obligations to avoid downstream approval setbacks. Overall, prudent scenario planning, flexible contract terms, and strengthened supplier relationships will be essential tools for mitigating the cumulative impacts of trade policy shifts on biologics development and commercialization.

Segmentation-driven insights revealing how service types, expression platforms, therapeutic focus, development phase needs, and end-user profiles dictate CDMO capabilities and strategic priorities

A nuanced segmentation lens reveals meaningful differences in demand drivers, operational requirements, and value propositions across service types, expression systems, therapeutic categories, development phases, and end users. Based on service type, the market distinguishes between drug product and drug substance services, each demanding specific technical capabilities and regulatory processes and prompting different partner selection criteria. Based on expression system, providers and sponsors evaluate trade-offs between mammalian and microbial platforms; mammalian systems require deep expertise in Cho, Hek, and Ns0 cell lines for complex glycosylated proteins, while microbial approaches such as E coli and yeast excel at rapid, cost-effective production for less complex molecules.

Based on therapeutic category, customer requirements vary significantly across immunology, infectious disease, neurology, and oncology, with oncology often necessitating highly tailored development pathways and immunology prioritizing robust scale-up capability. Based on development phase, needs evolve from preclinical and Phase I, where speed and flexibility are paramount, through Phase II and Phase III, where process robustness and scalable supply chain architectures become critical, to commercial stage where long-term capacity commitments, regulatory stability, and cost efficiency dominate decision criteria. Based on end user, expectations differ between biotech small and medium enterprises, contract research organizations, and large pharmaceutical firms; smaller biotech clients often prioritize agility and deep technical partnership, while large pharma typically seeks integrated global networks and stringent compliance systems. Together, these segmentation dimensions define the contours of demand and inform where investments in capability, quality systems, and commercial models will deliver the greatest strategic value.

Regional landscape analysis showing how the Americas, Europe Middle East & Africa, and Asia-Pacific each present distinct advantages and strategic considerations for biologics manufacturing

Regional dynamics continue to shape investment decisions, operational footprints, and partnership strategies across the global biologics manufacturing landscape. In the Americas, strengths include established regulatory frameworks, deep capital pools for facility expansion, and a concentration of sponsors requiring large-scale mammalian manufacturing capacity; this region often emphasizes integration with domestic clinical development programs and prioritizes supply chain resilience through localized capabilities. Europe, Middle East & Africa present a heterogeneous landscape where regulatory harmonization efforts coexist with regional specialization, enabling a mix of high-quality contract services for both niche and commercial-scale programs and fostering collaboration across national centers of excellence.

Asia-Pacific is distinguished by rapid capacity growth, competitive cost structures, and an expanding pool of technical talent, making it an important hub for both early-stage development work and commercial manufacturing for export-oriented clients. However, cross-border regulatory alignment and technology transfer considerations remain important when leveraging regional capacity. Across all regions, stakeholders increasingly factor in geopolitical dynamics, logistics complexity, and the availability of skilled workforce when making siting and partnership decisions. Strategic regional diversification, coupled with adherence to global quality standards and proactive regulatory planning, helps sponsors manage operational risk while accessing the advantages each region offers for different phases of product development and commercialization.

Corporate strategies and capability-building trends among major and niche service providers that are driving competitive differentiation and long-term resilience in biologics manufacturing

Leading companies and innovative entrants are pursuing differentiated strategies to secure resilient revenue streams and technological leadership in biologics contract development and manufacturing. Many incumbent providers are expanding end-to-end capabilities to capture value across drug substance and drug product workflows, investing in modular facilities and single-use platforms to increase throughput flexibility while lowering up-front capital intensity. Others are focusing on specialized niches, such as advanced analytics, high-potency manufacturing, or gene and cell therapy supply chains, to command premium positioning where deep scientific expertise is a decisive competitive moat.

Strategic partnerships and alliance models are increasingly prominent, with sponsors seeking collaborators that can co-invest in platform development or capacity expansions. Digitalization and automation investments are being leveraged not only to increase operational efficiency but also to enhance data integrity, regulatory readiness, and remote process monitoring-capabilities that are especially attractive to global pharmaceutical clients. Talent and knowledge management remain critical differentiators; firms that combine robust training programs with cross-functional scientific teams are better positioned to support complex transfer projects and accelerated timelines. Finally, environmental, social, and governance priorities are becoming integral to corporate strategies, with sustainability initiatives increasingly influencing customer selection and long-term contractual negotiations.

Practical, high-impact actions that senior executives and operational leaders can implement to improve flexibility, reduce execution risk, and strengthen competitive positioning in biologics CDMO operations

Industry leaders can take decisive steps to preserve agility, manage risk, and capture growth opportunities in a rapidly evolving biologics manufacturing ecosystem. First, prioritize flexible platform investments that support multiple expression systems and scalable downstream processing to accommodate shifting client mixes and therapeutic modalities; such flexibility reduces revalidation burdens and shortens technology transfer timelines. Second, strengthen supplier relationships through multi-year strategic agreements with clear governance and contingency clauses that address trade policy volatility and raw material availability. Third, accelerate adoption of digital process control and advanced analytics to improve yield, reduce batch failures, and demonstrate superior data integrity to regulators.

In addition, diversify regional capacity strategically rather than uniformly, aligning facility types to regional advantages-early-phase development hubs in regions offering rapid turnaround and commercial-scale production in regions with proven regulatory alignment. Invest in workforce development and cross-training programs to mitigate talent bottlenecks and ensure continuity during scale-up or transfer activities. Finally, incorporate sustainability and ESG metrics into operational planning to meet emerging customer expectations and regulatory disclosure trends; this includes evaluating circular supply chain opportunities for single-use systems and reducing energy and water footprints where feasible. By implementing these measures, leaders can reduce execution risk, improve customer retention, and position their organizations for sustained competitiveness in a dynamic market.

A transparent and rigorous research methodology combining expert interviews, documentation review, and data triangulation to produce validated actionable insights for biologics manufacturing stakeholders

The research underpinning these insights was developed through a structured methodology that combined targeted primary engagement with subject-matter experts and rigorous secondary-source validation. Primary research included in-depth interviews with technical leaders, regulatory affairs professionals, and commercial executives across a spectrum of sponsors and service providers, enabling nuanced understanding of operational constraints and customer decision criteria. Secondary research involved a systematic review of regulatory guidance, patent landscapes, technology white papers, and publicly available company disclosures to contextualize primary findings and identify persistent industry patterns.

Data triangulation was applied throughout to reconcile divergent perspectives and validate conclusions, with special attention given to cross-referencing interview findings against facility filings, regulatory approvals, and equipment vendor capabilities. Segmentation mapping was employed to align capability indicators with service types, expression systems, therapeutic categories, development phases, and end-user profiles, ensuring that recommendations were grounded in empirically observed behaviors. Finally, limitations and potential biases were explicitly considered, including geographic sampling constraints and respondent confidentiality concerns, and were mitigated through methodological transparency and iterative validation with independent experts.

A concise conclusion emphasizing the strategic shifts, imperative investments, and collaborative approaches needed to thrive in the evolving biologics CDMO ecosystem

In conclusion, the biologics contract development and manufacturing sector is being reshaped by technological innovation, evolving sponsor preferences, and an increasingly complex geopolitical and regulatory environment. These forces are driving a shift toward more strategic, integrated partnerships and compelling service providers to invest in flexible platforms, enhanced analytics, and robust quality systems. Sponsors, in turn, are seeking partners that can balance speed with regulatory rigor and provide secure, diversified supply chains capable of supporting both rapid development and long-term commercialization.

Looking forward, organizations that proactively address tariff-driven supply risks, align regional investments with strategic therapeutic priorities, and adopt digital and sustainability-focused practices will be better positioned to meet the demands of next-generation biologics programs. Collaboration across the ecosystem-between technology vendors, contract providers, and sponsors-will be critical to accelerate capability development and to ensure that operational changes translate into reliable patient access. The collective ability to manage complexity while maintaining regulatory compliance and scientific excellence will determine which organizations emerge as preferred long-term partners in the biologics era.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Biologics Contract Development & Manufacturing Organization Market, by Service Type

  • 8.1. Drug Product
  • 8.2. Drug Substance

9. Biologics Contract Development & Manufacturing Organization Market, by Expression System

  • 9.1. Mammalian
    • 9.1.1. Cho
    • 9.1.2. Hek
    • 9.1.3. Ns0
  • 9.2. Microbial
    • 9.2.1. E Coli
    • 9.2.2. Yeast

10. Biologics Contract Development & Manufacturing Organization Market, by Therapeutic Category

  • 10.1. Immunology
  • 10.2. Infectious Disease
  • 10.3. Neurology
  • 10.4. Oncology

11. Biologics Contract Development & Manufacturing Organization Market, by Development Phase

  • 11.1. Commercial
  • 11.2. Phase I
  • 11.3. Phase Ii
  • 11.4. Phase Iii
  • 11.5. Preclinical

12. Biologics Contract Development & Manufacturing Organization Market, by End User

  • 12.1. Biotech Small Med
  • 12.2. Contract Research Org
  • 12.3. Large Pharma

13. Biologics Contract Development & Manufacturing Organization Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Biologics Contract Development & Manufacturing Organization Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Biologics Contract Development & Manufacturing Organization Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Biologics Contract Development & Manufacturing Organization Market

17. China Biologics Contract Development & Manufacturing Organization Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. AbbVie, Inc.
  • 18.6. Abzena Ltd.
  • 18.7. Aenova Holding GmbH
  • 18.8. AGC Biologics GmbH
  • 18.9. Avid Bioservices, Inc.
  • 18.10. Binex Co. Limited
  • 18.11. Boehringer Ingelheim International GmbH
  • 18.12. Cambrex Corporation
  • 18.13. Catalent, Inc.
  • 18.14. Emergent BioSolutions, Inc.
  • 18.15. Fujifilm Holdings Corporation
  • 18.16. Icon PLC
  • 18.17. JSR Life Sciences, LLC
  • 18.18. Jubilant Biosys Limited
  • 18.19. Lonza Group AG
  • 18.20. Parexel International Corporation
  • 18.21. ProBioGen AG
  • 18.22. Recipharm AB
  • 18.23. Rentschler Biopharma SE
  • 18.24. Samsung Biologics
  • 18.25. Takeda Pharmaceutical Company Limited
  • 18.26. Tegra Medical
  • 18.27. Thermo Fisher Scientific, Inc.
  • 18.28. Toyobo Co., Ltd.
  • 18.29. WuXi Biologics Inc

LIST OF FIGURES

  • FIGURE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG PRODUCT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DRUG SUBSTANCE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CHO, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY HEK, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NS0, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY E COLI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY YEAST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY INFECTIOUS DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COMMERCIAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE I, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE II, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PHASE III, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY PRECLINICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY BIOTECH SMALL MED, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY CONTRACT RESEARCH ORG, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY LARGE PHARMA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 76. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 77. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 78. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 79. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 80. AMERICAS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 83. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 84. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 85. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 86. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 87. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 88. NORTH AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 92. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 93. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 94. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 95. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 96. LATIN AMERICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 111. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 112. EUROPE BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 116. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 117. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 118. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 119. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 120. MIDDLE EAST BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 124. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 125. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 126. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 141. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 142. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 143. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 144. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 145. ASEAN BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 148. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 149. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 150. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 151. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 152. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 153. GCC BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 156. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 157. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 158. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 159. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 160. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 161. EUROPEAN UNION BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 170. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 173. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 174. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 175. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 176. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 177. G7 BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 181. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 182. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 183. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 184. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 185. NATO BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 186. GLOBAL BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 190. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 191. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 192. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 193. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 194. UNITED STATES BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY SERVICE TYPE, 2018-2032 (USD MILLION)
  • TABLE 197. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY EXPRESSION SYSTEM, 2018-2032 (USD MILLION)
  • TABLE 198. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MAMMALIAN, 2018-2032 (USD MILLION)
  • TABLE 199. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY MICROBIAL, 2018-2032 (USD MILLION)
  • TABLE 200. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY THERAPEUTIC CATEGORY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY DEVELOPMENT PHASE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BIOLOGICS CONTRACT DEVELOPMENT & MANUFACTURING ORGANIZATION MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)